RTW
NEUTRALRTW Biotech Opportunities Ltd Announces Director Share Purchase
The retailer has announced a director has purchased 15,000 shares in the company.
RTW Biotech Opportunities Ltd
1.1800USD
0.00%
Market Cap
391.13M
Volume
0
NaN% of avg
P/E Ratio
N/A
EPS (TTM)
N/A
Beta
N/A
Day Range
1.1450p - 1.2000p
52 Week Range
N/Ap1.1800pN/Ap
1.1800p
Upcoming Events
H2 2025
JADE-001 to enter the clinic
High Impact Event
H1 2026
Initial data for JADE-001 expected
High Impact Event
RTW
NEUTRALRTW Biotech Opportunities Ltd Provides Portfolio Updates
The investment company provides updates on its portfolio, including positive clinical data from Taysha Gene Therapies and developments at Rocket Pharmaceuticals and Merus.
RTW
NEUTRALRocket Pharmaceuticals Provides Positive Update on RP-A601 Phase 1 Trial
The investment company provides an update on positive preliminary data from a Phase 1 trial of a gene therapy treatment being developed by one of its portfolio companies.
RTW
NEUTRALRTW Biotech Opportunities Ltd Announces Annual General Meeting
The biotech investment fund announces its upcoming Annual General Meeting, providing details on the event and how shareholders can participate.
RTW
NEUTRALRTW Biotech Opportunities Provides Update on Artios Pharma
The investment company provides an update on its portfolio company Artios Pharma, highlighting positive data from a clinical study of Artios' lead candidate.
RTW
NEUTRALJade Biosciences merges with Aerovate Therapeutics
The biotechnology company has announced the closing of a merger between two of its portfolio companies, Jade Biosciences and Aerovate Therapeutics.
RTW
NEUTRALRTW Biotech Opportunities Ltd Publishes Annual Financial Report
The investment fund has published its annual financial report, providing an update on its activities and performance over the past year.
RTW
NEUTRALRTW Biotech Opportunities Ltd Announces Director Shareholding
The company has disclosed a director's purchase of 50,000 shares in the business.
RTW
NEUTRALRTW Biotech Opportunities Invests in Biotech Firm AIRNA
The investment company has made a new investment in a biotech firm developing innovative RNA-editing therapies.
RTW
BADRTW Biotech Opportunities Reports Mixed Results Amid Challenging Biotech Landscape
The investment firm reported a 4.6% decline in NAV per share and underperformed key biotech indices. Despite growing total assets, increased liabilities and slower investment gains point to ongoing sector challenges.